Goldman Sachs raises Rhythm Pharmaceuticals stock price target on HO launch outlook

Goldman Sachs raised its price target on Rhythm Pharmaceuticals (RYTM) to $157 from $138 with a Buy rating, driven by a reinforced positive outlook for setmelanotide in hypothalamic obesity (HO) ahead of its December 2025 PDUFA date, projecting peak sales of $2.3 billion. This upgrade, supported by strong Q2 2025 IMCIVREE sales and similar target increases from other firms, reflects growing confidence in RYTM's commercial execution, exceptional margins, and a significantly larger addressable HO market. The company's strategic targeting of 2,000 HO patients and 2,400 physicians, benefiting from structural adoption advantages, positions it for robust growth.

Analysis

Rhythm Pharmaceuticals (RYTM) has received a series of significant price target upgrades from major investment banks, reflecting strong bullish sentiment driven by the commercial potential of its drug, setmelanotide, for hypothalamic obesity (HO). Goldman Sachs raised its target to $157, projecting $2.3 billion in peak sales for this indication, with similar upward revisions from Morgan Stanley (to $122), Citizens JMP (to $135), and H.C. Wainwright (to $100). This optimism is anchored to key regulatory milestones, including the FDA's acceptance of a supplemental New Drug Application for setmelanotide with a PDUFA date of December 20, 2025, and a parallel review by the European Medicines Agency. The company's financial and operational performance reinforces this positive outlook, with Q2 2025 global sales of IMCIVREE reaching $48.5 million (a 29% increase QoQ), an exceptional gross profit margin of 89.25%, and last-twelve-months revenue growth of 53.55%. The company's strategy for the HO launch, targeting an initial 2,000 patients, is considered favorable compared to its prior successful launch in Bardet-Biedl syndrome, suggesting a potentially faster adoption curve.

Key Decisions for Investors

• Given the strong analyst consensus, robust sales momentum, and a de-risked regulatory path for the large hypothalamic obesity market, investors may consider the stock's current valuation as a position to build ahead of significant potential growth.
• The primary catalyst to monitor is the December 20, 2025 PDUFA date for setmelanotide; any communication from the FDA or EMA regarding the drug's approval process will be a major driver of share price.
• Investors should scrutinize upcoming quarterly earnings for continued commercial execution, particularly the revenue growth of existing product IMCIVREE, to ensure performance justifies the stock's 83% six-month rally and the bullish analyst targets.